Pollution; ExposureNCT07229131
Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses
A study testing Acerola Juice Powder 1200 mg/day and Acerola Juice Powder 600 mg/day in people with Pollution; Exposure, run by Diana SAS at 1 site in China.
Trial summary
The study is being conducted to evaluate the efficacy and the safety of an oral acerola-based product on skin ageing parameters. Read more about this study
- Who is it for?
- Ages 30 to 60 years, women only
- Conditions the study is for
- Pollution; Exposure
- What is being tested?
- Acerola Juice Powder 1200 mg/day and Acerola Juice Powder 600 mg/day
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 108 participants
- Where
- 1 siteChina
- Study dates
- 3 Nov 2025to 13 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Healthy women.
- Chinese.
- Age: in each group of products
- 50% of subject having 30 to 45 years old
- 50% of subject having 46 to 60 years old
- Phototype: II to IV.
Show all 14Show fewer
- Subject with dull skin from grade 3 to 7 on skin dullness 9 points scale.
- Subject exposed to high air pollution up to 2 to 3 hours per day (traffic roads, cigarette smoke, dusts or small particles).
- Subject who accepts daily exposition to blue light (mobile phone, Ipad, laptop or get exposure to LED light) at home (at least 2h).
- Subject with at least 1 spot on the face.
- Subject with BMI ≤ 30
- Subject, psychologically able to understand the study related information and to give a written informed consent.
- Subject having given freely and expressly her informed consent.
- Subject agreeing to not change her alimentary and cosmetic habits on the studied area during the study.
Who cannot join
- In term of population :
- Pregnant or nursing woman or planning a pregnancy during the study.
- Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
- Minor subject.
- Major subject who is under guardianship or who is not able to express her consent.
- Subject in a social or sanitary establishment.
Show all 27Show fewer
- Subject suspected to be non-compliant according to the investigator's judgment.
- In term of associated pathology :
- Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
- Subject suffering from a severe or progressive disease.
- Subject with known history of or suffering from skin disease that may interfere with evaluation of the study results and/or subject safety.
- Subject having history of severe allergy or anaphylactic shock including known risk of hypersensitivity to one of the components of the composition of the product
- Related to previous or ongoing treatment :
- Subject undergoing a topical treatment on the test area or a systemic treatment:
- anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;
- corticosteroids during the 2 previous weeks and during the study;
- retinoids and/or immunosuppressors during the 3 previous months and during the study;
- any medication stabilized for less than one month.
- Subject having started or changed her oral contraceptive or any other hormonal treatment during the three previous months.
- Subject having done facial skin care like peeling, mask… during the previous 2 weeks and during the study.
- Subject having used oral nutritional supplements and/or vitamin supplementation during the previous month and during the study
- In term of lifestyle :
- Intensive exposure to sunlight or UV-rays within the previous month and/or foreseen during the study;
- Subject having used topical products containing actives substances during the previous 2 weeks and during the study
- Subject planning to change her life habits during the study.
- Subject with unstable eating habits or planning to change them during the study
- Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 5 cigarettes per day).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses: A Double-blind, Randomised, Placebo-controlled Study.
The study is being conducted to evaluate the efficacy and the safety of an oral acerola-based product on skin ageing parameters.
Read the detailed description
The main objective of this study is to assess efficacy of the product on skin translucency after 84 days of product compared to a placebo. The study will also evaluate the effect of the product on different skin parameters (radiance, firmness, elasticity, skin barrier function, skin pH, blood flow) with different instruments. The quality of life and the improvement of skin properties will also be collected with questionnaires completed by the subjects. Finally, the safety of this product will be assessed by collecting all adverse events that might occur during the study.
- Conditions
- Pollution; Exposure
- Being tested
- Acerola Juice Powder 1200 mg/day, Acerola Juice Powder 600 mg/day, Placebo
- Keywords
- Skin, Beauty, Environmental stress, Acerola, Vitamin C, Polyphenols
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acerola Juice Powder 1200 mg/dayDietary supplement
4 capsules per day, each capsule containing 300mg of Acerola and 100 mg of maltodextrin
Acerola Juice Powder 600 mg/dayDietary supplement
4 capsules/day, each capsule containing 150 mg of Acerola and 250 mg of Maltodextrin
PlaceboOther
4 capsules per day, each capsule containing 400 mg of maltodextrin
| Study group | Role | What they receive |
|---|---|---|
| Acerola Juice Powder 1200 mg/day | Experimental | Higher dose Receives: Dietary Supplement: Acerola Juice Powder 1200 mg/day |
| Acerola Juice Powder 600 mg/day | Experimental | Lower dose Receives: Dietary Supplement: Acerola Juice Powder 600 mg/day |
| Placebo | Placebo comparator | Placebo Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline on skin translucency parameter Alpha at 84 days
The skin translucency parameter Alpha is measured with translucency meter
Measured: From enrollment to 84 days of supplementation
Secondary outcomes (6)
Change from baseline on skin translucency parameters Alpha, Area and K at 28 days and 84 days
The skin translucency parameters Alpha, Area and Kis are measured with translucency meter
Measured: From enrollment to 28 days of supplementation
Change from baseline on skin complexion radiance at 14, 28, 56 and 84 days
Skin complexion radiance measured with Colorface®
Measured: From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on pigment spot at 14, 28, 56 and 84 days
Pigment spot measured with Colorface®
Measured: From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on skin firmness, elasticity and fatigability at 28 and 84 days
Skin firmness, elasticity and fatigability measured with Cutometer®
Measured: From enrollment to 28 and 84 days of supplementation
Change from baseline on Trans Epidermal Water Loss at 28 and 84 days
Trans Epidermal Water Loss measured with Tewameter®
Measured: From enrollment to 28 and 84 days of supplementation
Product safety
Safety assessed by the collection of adverse events and concomitant treatments throughout the study
Measured: From enrolment to 84 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2025
- Study start3 Nov 2025
- Primary completion13 Feb 2026
- Study completion13 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pollution; ExposureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double-blind, randomised, placebo-controlled study
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 108 participants (actual)
Sponsor and investigators
- Lead sponsor
- Diana SAS
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Eurofins Dermscan Pharmascan
- Responsible party
- Sponsor
- Investigators
- Sarah ZENG, Principal investigator, EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07229131
- Sponsor's protocol ID
- GZ25205020P
- Status last verified
- Feb 2026
- First submitted
- 13 Nov 2025
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of an Oral Acerola Juice Powder on Skin Beauty Parameters in Women Exposed to Environmental Stresses: A Double-blind, Randomised, Placebo-controlled Study.
- ClinicalTrials.gov ID
- NCT07229131
- Acronym / sponsor ID
- GZ25205020P
- Conditions
- Pollution; Exposure
- Keywords
- Skin, Beauty, Environmental stress, Acerola, Vitamin C, Polyphenols
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 108 participants (actual)
- Lead sponsor
- Diana SASIndustry (pharma, biotech, devices)
- Collaborators
- Eurofins Dermscan Pharmascan
- Study start
- 3 Nov 2025 (actual)
- Primary completion
- 13 Feb 2026 (actual)
- Study completion
- 13 Feb 2026 (actual)
- First posted
- 14 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is being conducted to evaluate the efficacy and the safety of an oral acerola-based product on skin ageing parameters.
Detailed description
The main objective of this study is to assess efficacy of the product on skin translucency after 84 days of product compared to a placebo. The study will also evaluate the effect of the product on different skin parameters (radiance, firmness, elasticity, skin barrier function, skin pH, blood flow) with different instruments. The quality of life and the improvement of skin properties will also be collected with questionnaires completed by the subjects. Finally, the safety of this product will be assessed by collecting all adverse events that might occur during the study.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Double-blind, randomised, placebo-controlled study
| Arm | Type | Receives |
|---|---|---|
| Acerola Juice Powder 1200 mg/day | Experimental | Dietary Supplement: Acerola Juice Powder 1200 mg/dayHigher dose |
| Acerola Juice Powder 600 mg/day | Experimental | Dietary Supplement: Acerola Juice Powder 600 mg/dayLower dose |
| Placebo | Placebo comparator | Other: PlaceboPlacebo |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- Healthy women.
- Chinese.
- Age: in each group of products
- Phototype: II to IV.
- Subject with dull skin from grade 3 to 7 on skin dullness 9 points scale.
Key exclusion criteria (27 listed)
- Pregnant or nursing woman or planning a pregnancy during the study.
- Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
- Minor subject.
- Major subject who is under guardianship or who is not able to express her consent.
- Subject in a social or sanitary establishment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acerola Juice Powder 1200 mg/day4 capsules per day, each capsule containing 300mg of Acerola and 100 mg of maltodextrin | Dietary supplement | Acerola Juice Powder 1200 mg/day |
| Acerola Juice Powder 600 mg/day4 capsules/day, each capsule containing 150 mg of Acerola and 250 mg of Maltodextrin | Dietary supplement | Acerola Juice Powder 600 mg/day |
| Placebo4 capsules per day, each capsule containing 400 mg of maltodextrin | Other | Placebo |
Primary outcome
Change from baseline on skin translucency parameter Alpha at 84 days
Time frame: From enrollment to 84 days of supplementation
The skin translucency parameter Alpha is measured with translucency meter
6 secondary outcomes
Change from baseline on skin translucency parameters Alpha, Area and K at 28 days and 84 days
Time frame: From enrollment to 28 days of supplementation
Change from baseline on skin complexion radiance at 14, 28, 56 and 84 days
Time frame: From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on pigment spot at 14, 28, 56 and 84 days
Time frame: From enrollment to 14, 28, 56 and 84 days of supplementation
Change from baseline on skin firmness, elasticity and fatigability at 28 and 84 days
Time frame: From enrollment to 28 and 84 days of supplementation
Change from baseline on Trans Epidermal Water Loss at 28 and 84 days
Time frame: From enrollment to 28 and 84 days of supplementation
Product safety
Time frame: From enrolment to 84 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Pollution; Exposure
Not yet recruiting
Reducing Exposure With Air Cleaners and Technology
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
Recruiting
Ambient Air and Noise Effect on Cardiovascular Health Risk and Lifestyle Intervention to Attenuate It (METSGREEN)
Cardiovascular Diseases (CVD), Metabolic Syndrome
Recruiting
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in Canada
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Recruiting
Voices Illuminating Solutions for Outdoor Workers' Needs and Safety
Air Pollution Exposure
Active, not recruiting
Effect of an Antioxidant Dietary Supplement on Skin Radiance
Healthy Women
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah ZENG principal investigator
EUROFINS CONSUMER PRODUCT TESTING (Guangzhou)Co.,Ltd.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acerola Juice Powder 1200 mg/day and Acerola Juice Powder 600 mg/day in people with Pollution; Exposure, run by Diana SAS at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline on skin translucency parameter Alpha at 84 days (time frame: From enrollment to 84 days of supplementation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.